A shadow market for unlicensed weight-loss drugs is being driven by social media fitness personalities and sellers on messaging platforms, based on recent findings.
Investigational Drug Acquiring Traction Via Social Media
Retatrutide, which is still in clinical trials, is being advertised by social media influencers for its alleged weight-reducing properties. Followers are urged to message these profiles directly for supplier links, while also obtaining promotional offers.
Active Trade on Social Networks
Additionally, a robust trade exists on messaging services, where groups with thousands of participants share “before and after” photos, administration instructions and claims of next-day UK delivery. Vendors promote the substance there before directing buyers to other platforms for transactions.
Learning About The Experimental Drug
This medication is an experimental injection created by American pharmaceutical company Eli Lilly. The treatment affects three gut hormones – glucagon-like peptide-1, GIP and glucagon. Preliminary studies suggest it could help individuals reduce up to a quarter of their total weight. Nicknamed the “triple G”, the drug is being hailed online as the next Ozempic.
Healthcare Professionals Express Concerns
However, doctors and chemists have warned that the distribution of what remains an unapproved medication in the UK is worrisome and could result in individuals administering products of unknown origin.
Several professionals stated the demand for retatrutide could be linked to the increasing cost of licensed slimming products such as Mounjaro.
Legal Position and Enforcement
Selling the unapproved drug on social media or messaging apps is illegal in the UK, as it is an unapproved drug that must not be marketed or supplied for human use under the Human Medicines Regulations 2012.
Some content creators attempt to circumvent the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but advertising and supply can still violate pharmaceutical, marketing, and consumer laws, potentially leading to fines, legal action or imprisonment.
Platform Reaction and Material Removal
Based on the social media company, the service has removed problematic content and banned associated hashtags and query recommendations. The organization said it was committed to keeping the platform secure and allocating resources in enhancing compliance measures.
Digital Trading Operations
Investigations also found communities with up to nine thousand members marketing retatrutide using the platform's built-in search feature, which functions like a public directory. Typing “retatrutide” immediately displays groups with thousands of users, populated with images of weight loss, glowing reviews and detailed instructions for preparing or injecting at home.
Within moments of entering one group, a seller shared contact information, where the majority of transactions occur. The seller provided an guidebook and promised shipping within 48 hours. When asked whether the product was genuine, one vendor responded: “You can’t be sure.” Another shared a image of a alleged testing documentation. Not one asked about weight, medical conditions or past usage.
Item Details and Pricing
Inside these communities, posts display black plastic packages with Royal Mail labels, claiming to contain fresh supplies. One communication read: “It took eight of us to load them this morning.”
Buyers can select between powder vials, prepared at residence with purified liquid, or pre-filled injectors usually sold at £160 for 20 milligrams. When asked how much time a pen should last, vendors give conflicting answers ranging from a several days to “depends on your body”.
Platform Oversight and Safety Measures
A spokesperson for Telegram stated it regularly monitored harmful material on its platform including material that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.
Medical Expert Cautions
“People are injecting substances they can’t verify. Even if the science behind retatrutide is sound, these digital products may not include what they advertise,” stated Jason Murphy, the head of pharmaceutical services at Chemist4U.
A medical professional of Asda Online Doctor connected the surge in interest to current price rises for approved slimming drugs such as Mounjaro. “With costs increasing, patients are turning to online platforms. But fake treatments are extremely dangerous. You can’t be certain what’s contained or whether the environment they were made in was sterile,” she explained.
Her staff has previously seen patients injured by self-injection from unverified suppliers. “We understand the frustration, but purchasing from Telegram or WhatsApp is gambling with your health,” said the doctor. “These substances could be impure or incorrectly dosed.”
Manufacturer Statement
A representative from Eli Lilly said the substance was in third stage research studies and had not been reviewed or authorized by any regulatory agency anywhere in the world. “Consequently at this point no one can sell [it] for personal consumption,” they explained, noting that any product “misleadingly claiming itself as a company investigational substance not yet approved … may expose patients to potentially serious medical dangers”.
